THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 92 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2014. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $70,815,000 | +6.6% | 2,221,302 | +21.2% | 0.01% | -7.1% |
| Q3 2016 | $66,431,000 | +64.0% | 1,833,096 | +2.7% | 0.01% | +55.6% |
| Q2 2016 | $40,518,000 | +37.5% | 1,785,707 | +13.9% | 0.01% | +28.6% |
| Q1 2016 | $29,471,000 | +13.5% | 1,567,595 | -1.0% | 0.01% | +16.7% |
| Q4 2015 | $25,960,000 | +47.5% | 1,583,902 | -1.1% | 0.01% | +20.0% |
| Q3 2015 | $17,600,000 | -20.9% | 1,601,440 | -6.3% | 0.01% | 0.0% |
| Q2 2015 | $22,260,000 | -14.5% | 1,709,689 | +14.0% | 0.01% | -16.7% |
| Q1 2015 | $26,026,000 | +45.3% | 1,500,077 | +25.0% | 0.01% | +50.0% |
| Q4 2014 | $17,906,000 | +1.2% | 1,200,149 | +56.4% | 0.00% | -20.0% |
| Q3 2014 | $17,692,000 | -32.2% | 767,562 | -6.2% | 0.01% | -28.6% |
| Q2 2014 | $26,084,000 | – | 818,182 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
| Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
| Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
| Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
| Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
| Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
| Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
| Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |